MS Setback for Acorda (ACOR, BIIB)
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is taking it right on the chin this morning. The company announced that it has received a “refuse to file letter” from the FDA regarding its New Drug Application…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 345Arena’s Real Issue: Drugs Vs. Gym & Behavior Modification (ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is getting shelled this morning. The company released “positive study data” this morning on trials for its obesity treatment Lorcaserin. But the real issue around the results is that…
Osiris Crushed on Crohn’s Trial Design Flaw (OSIR)
Osiris Therapeutics, Inc. (NASDAQ: OSIR) is seeing its stock getting pounded this morning. The company announced that it was ending enrollment at 210 patients in its Phase III trial evaluating its Prochymal for Crohn’s…
Allergan May Join Sector Takeover Waves (AGN, GSK, DNA, PFE, WYE, MRK, SGP)
If the rumor mill has any truth to it, then Allergan Inc. (NYSE: GSK) may by the next biotech takeover target. There is roughly $150 billion in new equity investor capital that can be…
Genetech Merger Holdouts Face Dimming Hope (DNA)
The hope for a higher Genentech Inc. (NYSE: DNA) buyout price is getting smaller and smaller. After the companies agreed to a $95.00 per share merger, this was already assumed as the nearly certain…
Gilead Wins CV Therapeutics Bid; Higher Bid Coming? (GILD, CVTX)
Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash.
Pfizer’s Sutent Scores Another Pancreatic Tumor Win (PFE)
Pfizer Inc. (NYSE: PFE) is stopping its Phase III clinical trial of Sutent early. This is generally a scare over adverse events, but not in this case. Sutent apparently has shown such a significant…
Roche Buyout: For Genentech (DNA), A Game Well Played
Before Roche decided to try to buy the 44% of biotech company Genentech (DNA) that it did not already own the smaller firm traded at $75. Roche offered just over $86 a share. Genentech…
Moody’s Takes Jab At Pfizer (PFE)
Pfizer Inc. (NYSE: PFE) just got its long-term ratings downgraded by Moody’s. It is amazing that bond ratings agencies still get to operate in a business as usual manner, but they do. Long gone…
Wal-Mart’s (WMT) Bid To Save The Healthcare System
The AMA, the federal government, and most insurance companies and HMOs have been arguing that storing and updating medical records digitally is much more efficient than having them on paper. The argument is compelling.…
Merck’s (MRK) New Merger, Another Way To Save Money
Merck (MRK) is merging with Schering-Plough (SGP) in a deal that the companies say is worth $41.1 billion. In reality, Merck is making an acquisition. Its shares will be the currency to compete the…
Roche Capitulates (DNA)
Roche has apparently capitulated in its fight to take over Genentech Inc. (NYSE: DNA). Its cancer franchise and its pipeline, along with a shareholder proxy fight, finally made Roche tip its hand. The company’s…
Biotech Trader Alerts (DNDN, DNA, GENZ, PDLI)
We are seeing unusual trading activity so far this morning in shares of Dendreon Corp. (NASDAQ: DNDN), Genentech, Inc. (NYSE: DNA), Genzyme Corp. (NASDAQ: GENZ), and PDL BioPharma, Inc. (Nasdaq: PDLI).
Warning People About Prescription Drugs
For years, Americans have assumed that the FDA was set up to test drugs. If a treatment was not effective or was too dangerous for patients, it never made it to market. If drugs that were…
Myriad Did What??? A Stock Split? (MYGN)
How long has it been since a company announced a stock split? More importantly, when was the last from a fairly large company? I can’t recall that off the top of my head either. …